NVO - Eli Lilly Struggles To Keep Pace With Mounjaro Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy | Benzinga
After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs.
Eli Lilly shares have climbed 162% since the launch of Mounjaro in May 2022. Since mid-February, however, the shares have stalled, albeit around record levels.
The sideways move could be attributed to a lack of availability of its two latest blockbusters.
Sales of its new products, launched since 2022, that include both Mounjaro and its sister weight-loss treatment Zepbound, contributed $2.5 billion towards its total fourth-quarter revenues of $9.35 billion. And of this, Mounjaro alone recorded sales of $2.21 billion — up from $1.41 billion in the previous quarter.
This is indicative of the anti-obesity drug’s popularity. In fact, Amazon ...